Form 4: Alto Neuroscience Director Gwill York Acquires Stock Options

Director Gwill York acquired stock options in Alto Neuroscience, Inc. on May 13, 2025, according to a Form 4 filing.

Summary

• Gwill York, a director of Alto Neuroscience, Inc., acquired 15,287 stock options on May 13, 2025.
• The exercise price of the options is $2.37.
• The options vest on the earlier of the one-year anniversary of the grant date or the date of the Issuer's next Annual Meeting following the date of grant, subject to continuous service.
• The options expire on May 12, 2035.
• The options were granted pursuant to the Issuer's Non-Employee Director Compensation Policy and no consideration was paid by the reporting person.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a standard compensation practice. The acquisition of stock options by a director is generally viewed as a positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule incentivizes the director to remain with the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Director compensation packages often include stock options to align their interests with shareholders, a common practice across publicly traded companies.
• The vesting schedule and exercise price are typical components of stock option grants, designed to incentivize long-term performance.

Stakeholder Impact

• The grant of stock options to a director aligns their interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates

Keywords

Stock Options, Form 4, Director, Alto Neuroscience, ANRO, Beneficial Ownership